153 related articles for article (PubMed ID: 38791997)
1. Outcomes of Budesonide as a Treatment Option for Immune Checkpoint Inhibitor-Related Colitis in Patients with Cancer.
Machado AP; Shaikh AS; Saji A; Shatila M; Oliva IG; Wang Y; Shirwaikar Thomas A
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791997
[TBL] [Abstract][Full Text] [Related]
2. Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis.
Abu-Sbeih H; Ali FS; Wang X; Mallepally N; Chen E; Altan M; Bresalier RS; Charabaty A; Dadu R; Jazaeri A; Lashner B; Wang Y
J Immunother Cancer; 2019 Apr; 7(1):93. PubMed ID: 30940209
[TBL] [Abstract][Full Text] [Related]
3. Oral budesonide for induction of remission in ulcerative colitis.
Sherlock ME; MacDonald JK; Griffiths AM; Steinhart AH; Seow CH
Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD007698. PubMed ID: 26497719
[TBL] [Abstract][Full Text] [Related]
4. Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series.
Harvey C; Nahar KJ; McKeown J; Lo SN; Farag S; Yousaf N; Young K; Tas L; Meerveld-Eggink A; Blank C; Thomas A; McQuade J; Schilling B; Johnson DB; Huertas RM; Arance A; Lee J; Zimmer L; Long GV; Carlino MS; Wang Y; Menzies AM
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38296594
[TBL] [Abstract][Full Text] [Related]
5. Microbiome alteration via fecal microbiota transplantation is effective for refractory immune checkpoint inhibitor-induced colitis.
Halsey TM; Thomas AS; Hayase T; Ma W; Abu-Sbeih H; Sun B; Parra ER; Jiang ZD; DuPont HL; Sanchez C; El-Himri R; Brown A; Flores I; McDaniel L; Ortega Turrubiates M; Hensel M; Pham D; Watowich SS; Hayase E; Chang CC; Jenq RR; Wang Y
Sci Transl Med; 2023 Jun; 15(700):eabq4006. PubMed ID: 37315113
[TBL] [Abstract][Full Text] [Related]
6. Oral budesonide for induction of remission in ulcerative colitis.
Sherlock ME; Seow CH; Steinhart AH; Griffiths AM
Cochrane Database Syst Rev; 2010 Oct; (10):CD007698. PubMed ID: 20927762
[TBL] [Abstract][Full Text] [Related]
7. Impact of Selective Immunosuppressive Therapy on Subsequent Immune-Related Adverse Events After Immune Checkpoint Inhibitor-Induced Colitis Treatment.
Pizuorno Machado A; Shatila M; Glitza Oliva IC; Altan M; Siddiqui B; Zhou Y; Varatharajalu K; Zhang HC; Thomas A; Wang Y
Am J Clin Oncol; 2023 Aug; 46(8):360-365. PubMed ID: 37219360
[TBL] [Abstract][Full Text] [Related]
8. Safety Considerations with the Use of Corticosteroids and Biologic Therapies in Mild-to-Moderate Ulcerative Colitis.
Cross RK
Inflamm Bowel Dis; 2017 Oct; 23(10):1689-1701. PubMed ID: 28906290
[TBL] [Abstract][Full Text] [Related]
9. P067 Immune Checkpoint Inhibitor Colitis in a Community-Based Hospital System.
Rampersad A; Abrams G; Bauer C
Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S17-S18. PubMed ID: 37461984
[TBL] [Abstract][Full Text] [Related]
10. Characteristics and outcomes of cancer patients with pre-existing microscopic colitis after exposure to PD-1 and PD-L1 inhibitors.
Thomas AR; Liu C; Tong YT; Tan D; Altan M; Siddiqui BA; Shatila M; Khan A; Thomas AS; Wang Y
J Cancer Res Clin Oncol; 2023 Jul; 149(8):5429-5436. PubMed ID: 36451045
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of infliximab and corticosteroid therapy in checkpoint inhibitor-induced colitis.
Dahl EK; Abed OK; Kjeldsen J; Donia M; Svane IM; Dige A; Agnholt JS; Bjerrum JT; Seidelin JB
Aliment Pharmacol Ther; 2022 Nov; 56(9):1370-1382. PubMed ID: 36123319
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study.
Abu-Sbeih H; Ali FS; Alsaadi D; Jennings J; Luo W; Gong Z; Richards DM; Charabaty A; Wang Y
J Immunother Cancer; 2018 Dec; 6(1):142. PubMed ID: 30518410
[TBL] [Abstract][Full Text] [Related]
13. Mesalamine and cholestyramine for immune checkpoint inhibitor-mediated diarrhea and colitis.
Hollander B; Khurana S; Jacob JS; Altan M; Wang J; Zhao D; Varatharajalu K; Alasadi M; Thomas AS; Wang Y
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3637-3648. PubMed ID: 35972690
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of Immune Checkpoint Inhibitor-Induced Colitis: A Systematic Review.
Nakane T; Mitsuyama K; Yamauchi R; Kakuma T; Torimura T
Kurume Med J; 2023 Jul; 68(2):43-52. PubMed ID: 37100606
[TBL] [Abstract][Full Text] [Related]
15. Aminosalicylates for induction of remission or response in Crohn's disease.
Lim WC; Wang Y; MacDonald JK; Hanauer S
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD008870. PubMed ID: 27372735
[TBL] [Abstract][Full Text] [Related]
16. Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson.
Wang Y; Abu-Sbeih H; Mao E; Ali N; Ali FS; Qiao W; Lum P; Raju G; Shuttlesworth G; Stroehlein J; Diab A
J Immunother Cancer; 2018 May; 6(1):37. PubMed ID: 29747688
[TBL] [Abstract][Full Text] [Related]
17. Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis.
Middha P; Thummalapalli R; Betti MJ; Yao L; Quandt Z; Balaratnam K; Bejan CA; Cardenas E; Falcon CJ; Faleck DM; ; Gubens MA; Huntsman S; Johnson DB; Kachuri L; Khan K; Li M; Lovly CM; Murray MH; Patel D; Werking K; Xu Y; Zhan LJ; Balko JM; Liu G; Aldrich MC; Schoenfeld AJ; Ziv E
Nat Commun; 2024 Mar; 15(1):2568. PubMed ID: 38531883
[TBL] [Abstract][Full Text] [Related]
18. Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis.
Mooradian MJ; Wang DY; Coromilas A; Lumish M; Chen T; Giobbie-Hurder A; Johnson DB; Sullivan RJ; Dougan M
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32414860
[TBL] [Abstract][Full Text] [Related]
19. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
20. Budesonide treatment for microscopic colitis from immune checkpoint inhibitors.
Hughes MS; Molina GE; Chen ST; Zheng H; Deshpande V; Fadden R; Sullivan RJ; Dougan M
J Immunother Cancer; 2019 Nov; 7(1):292. PubMed ID: 31699151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
